Neurometrix Inc (NURO) Receives Consensus Recommendation of “Hold” from Brokerages

Neurometrix Inc (NASDAQ:NURO) has earned a consensus broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating.

Zacks has also assigned Neurometrix an industry rank of 166 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

Several analysts have issued reports on the company. ValuEngine raised Neurometrix from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Zacks Investment Research raised Neurometrix from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th.

An institutional investor recently raised its position in Neurometrix stock. Renaissance Technologies LLC grew its holdings in shares of Neurometrix Inc (NASDAQ:NURO) by 68.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 123,783 shares of the medical device company’s stock after purchasing an additional 50,200 shares during the period. Renaissance Technologies LLC owned approximately 5.27% of Neurometrix worth $214,000 at the end of the most recent quarter. Institutional investors and hedge funds own 5.69% of the company’s stock.

Shares of NASDAQ NURO opened at $1.40 on Wednesday. The firm has a market cap of $10.00, a price-to-earnings ratio of -0.12 and a beta of 0.25. Neurometrix has a 12-month low of $1.20 and a 12-month high of $5.84.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3337550/neurometrix-inc-nuro-receives-consensus-recommendation-of-hold-from-brokerages.html.

Neurometrix Company Profile

NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.

Get a free copy of the Zacks research report on Neurometrix (NURO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$0.49 EPS Expected for CBRE Group  This Quarter
$0.49 EPS Expected for CBRE Group This Quarter
Zacks: Brokerages Anticipate Hudson  Will Announce Earnings of $0.03 Per Share
Zacks: Brokerages Anticipate Hudson Will Announce Earnings of $0.03 Per Share
Extended Stay America  Stock Rating Reaffirmed by Robert W. Baird
Extended Stay America Stock Rating Reaffirmed by Robert W. Baird
Zacks Investment Research Downgrades Incyte  to Hold
Zacks Investment Research Downgrades Incyte to Hold
Zacks Investment Research Downgrades Tata Motors  to Sell
Zacks Investment Research Downgrades Tata Motors to Sell
RBB Bancorp  to Issue Quarterly Dividend of $0.09
RBB Bancorp to Issue Quarterly Dividend of $0.09


© 2006-2018 Ticker Report. Google+.